Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
| ▸ | ALPL | P05186 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | STAT3 | P40763 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10198378 | 0.90 | POLB (0.46) | POLBAPEX1CA12CA1CA2 | |
| SCHEMBL15036577 | 0.87 | POLB (0.37) | POLBAPEX1CA12CA1CA2 | |
| SCHEMBL364791 | 0.85 | POLB (0.40) | POLBAPEX1CA12CA1CA2 | |
| SCHEMBL3545080 | 0.85 | GAA (0.45) | POLBAPEX1CA12CA1CA2 | |
| SCHEMBL17244937 | 0.84 | SCN9A (0.36) | POLBAPEX1CA12CA1CA2 | |
| SCHEMBL15543791 | 0.84 | POLB (0.45) | POLBAPEX1CA12CA1CA2 | |
| SCHEMBL15544550 | 0.83 | SCN9A (0.36) | POLBAPEX1CA12CA1CA2 | |
| SCHEMBL15036521 | 0.82 | SCN9A (0.38) | POLBAPEX1CA12CA1CA2 | |
| SCHEMBL16178275 | 0.82 | POLB (0.34) | POLBAPEX1CA12CA1CA2 | |
| SCHEMBL10260913 | 0.81 | GABRG2 (0.36) | HTTNR3C2ALDH1A1GABRA1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11203572-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-11149002-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| EP-3854782-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20210155588-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-05-27 | — | — | US | disclosed |
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-04-01 | — | — | US | disclosed |
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-04-01 | — | — | US | disclosed |
| US-20210078947-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| EP-3436432-B1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2021-01-27 | — | — | EP | disclosed |
| US-10766858-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20200108054-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-09 | — | — | US | disclosed |
| EP-2593427-A1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | Pfizer Limited (GB) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007861-A1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012007861-A1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012007883-A1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012007883-A1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010207-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010207-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010207-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010183-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010183-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149002-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | POLB 2801/4885APEX1 3374/4885CA12 2381/4885 |
| US-20120010207-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | POLB 4438/4885APEX1 2170/4885CA12 3451/4885 |
| US-20210155588-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, RRM1 | POLB 1637/4885APEX1 4468/4885CA12 2125/4885 |
| US-11203572-B2 | Substituted benzamides and methods of use thereof | BRIX1, RDX, RRM1 | POLB 1637/4885APEX1 4468/4885CA12 2125/4885 |
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SULT2A1 | POLB 2569/4885APEX1 4632/4885CA12 2251/4885 |
| US-20120010183-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | POLB 4442/4885APEX1 2373/4885CA12 4548/4885 |
| US-10766858-B2 | Substituted benzamides and methods of use thereof | BRIX1, RDX, SULT2A1 | POLB 1848/4885APEX1 4491/4885CA12 1752/4885 |
| US-20210078947-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | POLB 2801/4885APEX1 3374/4885CA12 2381/4885 |
| US-20200108054-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SULT2A1 | POLB 2569/4885APEX1 4632/4885CA12 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.